Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Allergy Therapeutics ( (GB:AGY) ) has issued an update.
Allergy Therapeutics will present new clinical and biomarker data from its pollen and food-allergy research pipeline at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting in Philadelphia. The company emphasised that no new price-sensitive information will be disclosed at the event.
The group is highlighting Phase III results for its Grass MATA MPL short-course subcutaneous immunotherapy, including a statistically significant 22.5% reduction in symptom and medication scores versus placebo and favourable safety data in a paediatric trial cohort. It will also showcase positive safety, tolerability and interim biomarker data from its VLP Peanut Phase I/IIa trial, underlining the versatility of its platform and reinforcing its positioning in disease-modifying therapies following recent regulatory approval of Grass MATA MPL in Germany.
The most recent analyst rating on (GB:AGY) stock is a Sell with a £11.00 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Spark’s Take on GB:AGY Stock
According to Spark, TipRanks’ AI Analyst, GB:AGY is a Neutral.
The score is driven primarily by very weak financial performance (declining revenue, large losses, negative cash flows, and negative equity). Technicals are mixed with oversold signals but still negative momentum, and valuation is constrained by a negative P/E and no dividend support.
To see Spark’s full report on GB:AGY stock, click here.
More about Allergy Therapeutics
Allergy Therapeutics is a UK-headquartered international commercial biotechnology company focused on the treatment and diagnosis of allergic disorders, including aluminium-free allergy immunotherapies with disease-modifying potential. The group markets proprietary and third-party products across nine major European countries and through distributors in a further four markets, targeting patients with pollen and food allergies.
Average Trading Volume: 332,857
Technical Sentiment Signal: Buy
Current Market Cap: £718.5M
See more insights into AGY stock on TipRanks’ Stock Analysis page.